NCT07156149RECRUITING

Fabhalta Capsules Specified Drug-use Survey

Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)

Sponsor: Novartis Pharmaceuticals

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type

OBSERVATIONAL

Conditions

C3 Glomerulopathy

Interventions

—

Enrollment

50 participants

Primary completion

Jun 2028

Study completion

Jun 2028

First posted

Sep 2025

Last updated

Apr 2026

Primary Endpoints (CT.gov)

Number of patients with infections

Time frame: 360 Days

Secondary Endpoints

Incidence of adverse events and adverse reactions

Changes in UPCR

Changes in eGFR

Eligibility Criteria

Inclusion Criteria: * All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant). Exclusion Criteria: * Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov